Lifecore Biomedical Balans Gezondheid

Financiële gezondheid criteriumcontroles 1/6

Lifecore Biomedical heeft een totaal eigen vermogen van $39.5M en een totale schuld van $127.9M, wat de schuld-eigenvermogensverhouding op 323.8% brengt. De totale activa en totale passiva bedragen respectievelijk $246.8M en $207.3M.

Belangrijke informatie

323.8%

Verhouding schuld/eigen vermogen

US$127.92m

Schuld

Rente dekkingsratio	n/a
Contant	US$5.52m
Aandelen	US$39.50m
Totaal verplichtingen	US$207.32m
Totaal activa	US$246.82m

Recente financiële gezondheidsupdates

Recent updates

Lifecore Biomedical: Finally A 'Pure Play' CDMO Business

Nov 12

Lifecore Biomedical: No Sale Soon Amidst Leverage And Uncertainty

Jun 24

White Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF Surge

Apr 20

Analysts Have Been Trimming Their Landec Corporation (NASDAQ:LNDC) Price Target After Its Latest Report

Apr 08

Landec (NASDAQ:LNDC) Has A Somewhat Strained Balance Sheet

Mar 21

Here's What's Concerning About Landec's (NASDAQ:LNDC) Returns On Capital

Nov 30

Optimistic About Landec's Strategic Initiatives And Sodium Hyaluronate Products

Nov 05

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $74.2M ) LFCR } overtreffen de korte termijn passiva ( $40.5M ).

Langlopende schulden: De kortetermijnactiva van LFCR ( $74.2M ) dekken de langetermijnschulden ( $166.8M ) niet.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 309.9% ) LFCR wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van LFCR is de afgelopen 5 jaar gestegen van 62.7% naar 323.8%.

Schuldendekking: De schuld van LFCR wordt niet goed gedekt door de operationele kasstroom ( 5.8% ).

Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van LFCR op haar schulden goed worden gedekt door EBIT.

Lifecore Biomedical Balans Gezondheid

Financiële gezondheid criteriumcontroles 1/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Lifecore Biomedical, Inc. announced delayed annual 10-K filing

Lifecore Biomedical Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Requirements for Continued Listing Under Nasdaq Listing Rule 5620(a)

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Recent updates

Price target increased by 7.7% to US$7.00

High number of new directors

Lifecore Biomedical: Finally A 'Pure Play' CDMO Business

Lifecore Biomedical, Inc. Appoints Jackie Klecker as Executive Vice President, Quality and Development Services

Lifecore Biomedical, Inc. announced that it has received $24.307978 million in funding

Lifecore Biomedical, Inc. Reiterates Financial Guidance for Full Year Fiscal 2025

Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler Is Gmp-Ready and Operational

Lifecore Biomedical, Inc. Appoints Brikkelle Thompson as Senior Vice President of Human Resources

Lifecore Biomedical Announces Chief Financial Officer Transition

Lifecore Biomedical, Inc. Provides Earnings Guidance for Full Year Fiscal 2025

Lifecore Biomedical, Inc. announced delayed annual 10-K filing

Third quarter 2024 earnings released: EPS: US$0.48 (vs US$0.51 loss in 3Q 2023)

High number of new directors

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Lifecore Biomedical, Inc

Price target decreased by 25% to US$6.00

Lifecore Biomedical, Inc. Announces Board Changes

Lifecore Biomedical: No Sale Soon Amidst Leverage And Uncertainty

Lifecore Biomedical Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Requirements for Continued Listing Under Nasdaq Listing Rule 5620(a)

Lifecore Biomedical, Inc., Annual General Meeting, Aug 15, 2024

White Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF Surge

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024

Lifecore Biomedical, Inc. Announces Chief Executive Officer Changes, Effective May 20, 2024

Lifecore Biomedical Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual Report

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Would Lifecore Biomedical (NASDAQ:LFCR) Be Better Off With Less Debt?

Lifecore Biomedical, Inc.(NasdaqGS:LFCR) dropped from Russell 2000 Dynamic Index

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 86% to US$2.00

High number of new directors

Lifecore Biomedical Receives A Notification Letter from Nasdaq Due to Delay in Filing Its Quarterly Report on Form 10-Q for the Period Ended November 27, 2022

Lifecore Biomedical, Inc. announced that it has received $38.75 million in funding from Legion Partners Asset Management, LLC, 22NW, LP, 325 Capital, LLC, Cove Street Partners, Wynnefield Capital, Inc.

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. announced that it has received $5.003136 million in funding

Price target decreased to US$13.75

Landec Corporation Reiterates Revenue Guidance for the Full Year Fiscal 2023

Landec Non-GAAP EPS of -$0.32, revenue of $43.35M

Landec Corporation to Report Q1, 2023 Results on Oct 06, 2022

Landec Corporation, Annual General Meeting, Nov 01, 2022

Landec Corp. Receives Notice from Nasdaq Regarding Delayed Annual Report

Landec receives Nasdaq's notification on delayed annual report filing

Landec Corporation announced delayed annual 10-K filing

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Landec Corporation Provides Revenue Guidance for the Full Year Fiscal 2023

VP & President of Lifecore exercised options to buy US$76k worth of stock.

Laughing Water Capital - Landec Corp. : A High Quality CDMO

Landec Corporation(NasdaqGS:LNDC) dropped from Russell 2000 Value-Defensive Index

Landec (NASDAQ:LNDC) Takes On Some Risk With Its Use Of Debt

Independent Director exercised options to buy US$70k worth of stock.

CEO, President & Director exercised options to buy US$269k worth of stock.

High number of new directors

Analysts Have Been Trimming Their Landec Corporation (NASDAQ:LNDC) Price Target After Its Latest Report

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Landec Corporation Reiterates Consolidated Earnings Guidance for the Fiscal Year 2022

Landec (NASDAQ:LNDC) Has A Somewhat Strained Balance Sheet

High number of new directors

Independent Director recently bought US$104k worth of stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Landec Corporation Provides Consolidated Revenue Guidance for Full Year Fiscal 2022

Price target increased to US$15.00

Consensus revenue estimates fall by 66%

Here's What's Concerning About Landec's (NASDAQ:LNDC) Returns On Capital

Optimistic About Landec's Strategic Initiatives And Sodium Hyaluronate Products

Landec Corporation Provides Earnings Guidance for the First Half, Second Half and Full Year of Fiscal 2022

First quarter 2022 earnings released: US$322 loss per share (vs US$0.38 loss in 1Q 2021)